Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
PrEP: Australian advocates call for greater affordability and access to new preventative HIV method

Truvada is already listed under the pharmaceutical benefits scheme for use to treat people with HIV, but is not available for prevention. "We are incredibly keen to see this available through the PBS at scale quickly, very, very quickly," Darryl O'Donnell, CEO of the Australian Federation of AIDS Organisations said.

Published
9 hours ago
From
ABC
MP calls for PrEP manufacturer to submit to Scottish regulator

The Scottish Medicines Consortium is responsible for approving all drugs available on the NHS in Scotland and the Glasgow South MP has called for the company to make a submission, so it can form part of the country’s HIV prevention strategy.

Published
9 hours ago
From
Pink News
Survey finds good knowledge of PrEP in Europe and a considerable amount of unsupported informal PrEP use

A large survey of knowledge and use of pre-exposure prophylaxis (PrEP) in Europe released its preliminary results on World AIDS Day. The Flash!PrEP survey found high, though

Published
01 December 2016
By
Gus Cairns
Switching course, Gilead markets HIV drug for prevention

This fall, the drugmaker began marketing directly to consumers with print advertisements in publications geared toward the lesbian, gay, bisexual and transgender community, including OUT, Advocate and SWERV. It plans soon to expand to social media and digital.

Published
30 November 2016
From
Reuters
Jake Sobo: My life on PrEP—4 years later

We couldn’t be more excited to re-connect with one of our legendary contributors, Jake Sobo, for this feature on BETA. Back in 2012, Sobo was one of the first—if not the first—gay man to write openly about his experience taking PrEP for HIV prevention. He quickly became one of our most read and controversial authors—sparking debates online and off. We recently caught up with Jake to get an update on his life, hear his thoughts on the future of PrEP, and find out what he thinks about rising rates of sexually transmitted infections among gay men.

Published
30 November 2016
From
BETA blog
Argument over funding HIV PrEP drug reveals reluctance to tackle the realities of gay sex

Ignoring those at 'high risk' of HIV in order to sustain the idea of the 'good' gay man will only perpetuate the virus.

Published
22 November 2016
From
The Independent
Aid groups grapple with stigmatization in HIV prophylaxis roll-out

PrEP’s success in sub-Saharan Africa will hinge more on the social than the scientific. Researchers and advocates will have to strike a balance in how they market and roll out PrEP. They have to ensure that it reaches stigmatized populations with high HIV transmission rates, such as MSM and sex workers. Meanwhile, they must ensure it is not perceived as exclusively a treatment for marginalized groups, which will lower its appeal both within those communities but also to other people who could benefit from it.

Published
21 November 2016
From
Devex
DISCOVER Trial Factsheet

Fact sheet explaining the background to the DISCOVER trial

Published
17 November 2016
From
AIDS Foundation of Chicago
Community demand for temporary halt to Gilead DISCOVER study

A group of U.S., Canadian, and European community advocates and HIV NGO workers have written a letter exrpesing "deep dismay" that Gilead Sciences have proceeded with the DISCOVER trial PrEP"without engaging stakeholders in a substantial or meaningful way.". DISCOVER will compared Gilead's new comination pill, Descovy against Truvada as PrEP. In 2007, the HIV/AIDS field adopted Good Participatory Practice (GPP), a formal set of guidelines approved by UNAIDS for stakeholder engagement in HIV prevention clinical trials. "It is astonishing," says the letter, "that Gilead has failed to follow GPP guidelines in the design and implementation of DISCOVER, since GPP was developed partly as a response to the failure of previous prevention trials involving tenofovir."

Published
17 November 2016
From
HIV Prevention Justice Alliance
Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?

Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials.

Published
17 November 2016
From
The Body
← First12345...102Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.